Table 2.
Therapeutic Effect of Sialidase Inhibitors.
| Medicines | Object | Research design | Method of administration | Results of treatment | P-value | References |
|---|---|---|---|---|---|---|
| Oseltamivir | A 13-year-old girl with chronic ITP | – | Oral Oseltamivir 75 mg twice daily for 5 days with 30 days follow-up | After 16 days of Oseltamivir treatment, the patient’s platelet counts increased from 4 × 109/L to 97 × 109/L | – | (82) |
| Oseltamivir | A cohort of 10 female patients aged 5–79 years with chronic ITP | – | Oral Oseltamivir 75 mg twice daily for 5 days with a 6-month follow-up | After 6 months of Oseltamivir treatment, the patient exhibited a 40% response rate, and platelet counts increased from 16×109/L to 111×109/L | – | (83) |
| Oseltamivir | 385 adult patients with influenza A or B | Retrospective study | Oral Oseltamivir 0.99 mg (cumulative dose) | After 14 days of Oseltamivir administration, the two groups of patients receiving Oseltamivir demonstrated increased platelet counts of (57.53 ± 93.81) ×109/L, p=0.013, and (50.79 ± 70.59) ×109/L, p=0.023, respectively. These counts were significantly higher than those in the group without Oseltamivir, which remained at (18.45 ± 89.33) ×109/L | P<0.05 | (84) |
| Oseltamivir | 35 individuals diagnosed with ITP spanning ages 2 to 79 years | Multicenter, prospective study | Oral Oseltamivir 75 mg twice daily for 5 days with a 3-month follow-up | After 3 months of Oseltamivir treatment, the overall response rate was 66.7% (3 CR, 1 R) | P<0.05 | (85) |
| Dexamethasone combined with Oseltamivir | A group of 96 patients aged 18 years or older with newly diagnosed untreated ITP | Multicenter, randomized, open-label, parallel groups | Dexamethasone monotherapy (40 mg/day orally for 4 days) or combination therapy with dexamethasone (40 mg/day orally for 4 days) plus Oseltamivir (75 mg orally twice daily for 10 days) was administered, followed by a 6-month follow-up period. | After 14 days of administering Oseltamivir, patients in the Oseltamivir-co-dexamethasone group showed a notably higher initial remission rate (86%) compared to the decemethasone-only group (66%; odds ratio (OR) 3.18; 95 CI% 1.13–9.23). Furthermore, after 6 months of treatment, the rate of sustained remission was significantly higher in the Oseltamivir combined with dexamethasone group than in the dexamethasone-only group (23 (53%) vs. 14 (30%); OR 2.17; 95% CI 1.16–6.13) | P<0.05 | (86) |
| Oseltamivir | A set of 7 female patients aged 16–74 years with chronic, persistent, or refractory ITP | Prospective, single-group intervention study | Oral Oseltamivir 75 mg twice daily for 5 days with a 6-month follow-up | After 6 months of Oseltamivir treatment, 3 patients (42.9%) remained in remission and 1 patient developed a Complete Response (14.3%) | P<0.05 | (87) |